Minimally invasive surgery after chemotherapy for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies whether doing surgery using smaller incisions after chemotherapy works as well as a more traditional approach for certain people with stage IIIC–IV ovarian, fallopian tube, or primary peritoneal cancer. It may help reduce surgical trauma while aiming for effective tumor removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older.
- Have stage IIIC or IV high-grade ovarian, fallopian tube, or primary peritoneal cancer (or similar “high-grade Mullerian” cancer) and it has responded to initial chemotherapy.
- Finish 3 to 4 cycles of platinum-based chemotherapy (or follow a trial-specific chemotherapy plan), and your scans show no clear disease outside the belly/abdominal cavity (small fluid around the lungs may be allowed).
- Be planned to have “interval debulking” surgery within about 6 weeks (42 days) after the last chemotherapy cycle.
- Be well enough for surgery (ECOG “performance status” 0 to 2) and able to follow up as required.
- Have CA-125 blood tumor marker that meets study limits for your site, and be scheduled for a diagnostic laparoscopy if your CA-125 is ≤500.
- Not have tumor spread that surgeons consider unsafe for minimally invasive resection (for example, involving certain organs or areas like the bowel/stomach, diaphragm, spleen/liver surfaces, or extensive mesenteric disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using a small-scope (minimally invasive) surgery instead of a large incision can safely remove remaining ovarian cancer after chemotherapy. It may mean a faster recovery and fewer complications.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
This Phase 3 trial tests whether patients with advanced ovarian, fallopian tube, or primary peritoneal cancer do better with surgery first versus chemotherapy first. It also groups people based on how extensive the cancer is to choose the best approach.
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
This trial tests if laparoscopic surgery after 3-4 cycles of chemotherapy can help people with advanced epithelial ovarian cancer. It's for those whose tumors have shrunk enough after chemo and who are healthy enough for surgery.
Hear when a new Advanced Ovarian Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.